Shanghai Celgen To Buy Back Simcere's 35% Stake For $48.1 Million
This article was originally published in PharmAsia News
Executive Summary
Shanghai Celgen Bio-Pharmaceutical is about to buy back from Simcere Pharmaceutical Group all of its shares for $48.1 million in an all-China deal.